Business Segments BioCryst Pharmaceuticals, Inc.
Stocks
BCRX
US09058V1035
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-09-18 EDT
|
5-day change | 1st Jan Change | ||
| 8.680 USD | -0.23% |
|
+6.90% | +11.28% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Biotechnology (Startups) | 157M | 271M | 331M | 451M | 875M | |||||
Total Assets | 588M | 550M | 517M | 490M | 514M | |||||
Interest Expense | -59.29M | -99.09M | -108M | -98.52M | -78.87M | |||||
Income Tax Expense | 2.25M | 2.73M | 310K | 1.93M | 3.53M | |||||
CAPEX | -2.38M | -1.35M | -2.17M | -1.12M | -2.47M | |||||
EBT | -182M | -244M | -226M | -86.95M | 267M | |||||
D&A | 777K | 1.44M | 1.66M | 3.01M | 3.49M | |||||
Operating Income | -178M | -148M | -104M | -2.54M | 341M | |||||
Net Income | -184M | -247M | -227M | -88.88M | 264M |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | - | - | - | - | 549M | |||||
Total Assets | - | - | - | - | 514M | |||||
| - | - | - | - | 53.06M | ||||||
Unallocated | - | - | - | - | 273M | |||||
Outside United States | - | - | - | - | 53.06M | |||||
| - | - | - | - | 273M | ||||||
| - | - | - | - | 549M |
- Stock Market
- Stocks
- BCRX Stock
- Financials BioCryst Pharmaceuticals, Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
